Molecular techniques have been developed for prenatal diagnosis of the most common chromosome disorders (trisomies 21, 13, 18 and sex chromosome aneuploidies) where results are available within a day or two. This involves fluorescence in situ hybridization (FISH) and microscopy analysis of fetal cells or quantitative fluorescence polymerase chain reaction (QF-PCR) on fetal DNA. Guidance is provided on the technological pitfalls in setting up and running these methods. Both methods are reliable, and the risk for misdiagnosis is low, although slightly higher for FISH. FISH is also more labour intensive than QF-PCR, the latter lending itself more easily to automation. These tests have been used as a preamble to full chromosome analysis by microscopy. However, there is a trend to apply the tests as 'stand-alone' tests for women who are at relatively low risk of having a baby with a chromosome disorder, in particular that associated with advanced age or results of maternal serum screening programmes. These women comprise the majority of those currently offered prenatal diagnosis with respect to fetal chromosome disorders and if introduced on a larger scale, the use of FISH and QF-PCR would lead to substantial economical savings. The implication, on the other hand, is that around one in 500 to one in 1000 cases with a mentally and/or physically disabling chromosome disorder would remain undiagnosed.
Prenatal diagnosis with a view to identifying fetal genetic disorders started in the early 1970s. Since its inception, the most common reason for prenatal diagnosis is increased risk of having a child with trisomy 21 Down syndrome. This risk is dependent on maternal age, and is also assessed by maternal serum screening programmes and fetal ultrasonography (nuchal translucency). Other indications for prenatal diagnosis of chromosome disorders include additional structural fetal abnormalities detected by ultrasonography, a previous child with a chromosome disorder or either parent being a carrier of a chromosomal rearrangement.
Over the years prenatal diagnosis has become increasingly common; for example, to date it involves around 1 in 20 pregnant women in the UK. Fetal cells for chromosome diagnosis are obtained either by amniocentesis (usually at about 15 weeks of gestation) or chorionic villus sampling (at about 9-11 weeks of gestation). Both these procedures are invasive and carry an associated risk for induced abortion in approximately 1 in 100 to 1 in 200 women tested. Traditionally, chromosome diagnosis Email: maj.hulten@warwick.ac.uk is accomplished by karyotyping, that is, analysis of chromosomes by microscopy followed by the lining up of each chromosome pair (Fig. 1) .
Karyotyping, most often by Giemsa banding (Gbanding) is performed on fetal cells at the metaphase stage of the cell cycle, when chromosomes are optimally condensed. Amniotic fluid samples obtained by amniocentesis do not contain any fetal cells in division and have to be grown in vitro to obtain cells at the metaphase stage. In chorionic villus samples (CVSs), some fetal cells are spontaneously dividing and cells at metaphase can be used. However, the resolution (of special importance for the detection of structural abnormalities) may be quite low, as these spontaneously dividing cells have more condensed chromosomes than those obtained after cell culture in vitro. Another disadvantage of CVSs is the common occurrence of confined placental mosaicism, the occurrence of a proportion of aberrant cells that do not represent the chromosome status of the fetus. These aberrant cells when originating in cytotrophoblasts may be selected against during cell culture in vitro. Therefore, cell culture is usually performed as a follow-up to any direct chromosome diagnosis on CVSs. During the last three decades, improved technology for prenatal diagnosis by karyotyping has mainly involved devising methods for obtaining less condensed chromosomes and for reducing culture time.
The presence of a larger number of bands on longer chromosomes implies that subtler structural chromosome abnormalities may be detected. However, it is important to note that even at high resolution G-banding, deletions or duplications < 5 Mb will usually remain undetected. The implication is that a proportion of chromosome abnormalities, which may be associated with physical and mental disability, will not be routinely diagnosed, even with this 'gold standard' test.
In the early days, it took around 3-4 weeks of culture of amniocytes in vitro to obtain enough cells in division for karyotyping but substantial reduction in culture time of both amniocytes and chorionic villus cells has been achieved more recently. For example, from 1987 to 1998, the average reporting time in the UK decreased from 20.2 to 13.8 days for amniotic fluid samples and from 21.3 to 14.5 days for CVSs (Waters and Waters, 1999) . Some laboratories have been able to reduce the culture time in vitro even further (for example, see Miller and Peakman, 1999) .
It is recognized that long waiting times for results may cause much psychological suffering and this has been one of the main reasons for the introduction of molecular methods for prenatal diagnosis of common chromosome disorders. This type of approach does not require cell culture and reports can routinely be issued within 1-2 days.
Provision of rapid and simple detection of common fetal chromosome disorders
The two most common types of molecular method for prenatal diagnosis of chromosome disorders are fluorescence in situ hybridization (FISH) and the quantitative fluorescence polymerase chain reaction (QF-PCR). Both methods are now used routinely for rapid and simple diagnosis of aneuploidy (numerical chromosome abnormalities), including in particular trisomy 21, 13 and 18 (giving rise to the Down, Patau and Edward syndromes, respectively) and sex chromosome abnormalities (associated with the XXY-Klinefelter, XYY, XXX and X-Turner syndromes). The disorders listed above are the most common. Overall they comprise 70-80% of karyotyped abnormalities associated with physical-mental handicap. However, they constitute 99.8-99.9% in lowrisk pregnancies, in which women are tested because of maternal age, maternal serum or ultrasonographic screening for fetal nuchal translucency (for example, see Ward et al., 1993; Evans et al., 1999; Pergament et al., 2000; Thein et al., 2000; Grimshaw et al., 2003) . Notably, there is some variation among studies, and a much higher rate of residual abnormality has been identified in a recent study by Homer et al. (2003) .
FISH and QF-PCR involve DNA fluorescence but in different ways
FISH and QF-PCR both make use of fluorescence tagging of DNA, but chromosome diagnosis is accomplished by each in very different ways. Labelling with whole chromosome FISH probes specific for chromosome 9 (green) and chromosome 20 (red). Note that, in the metaphase, the chromosomes are distinctive but, in the interphase nuclei, they appear as fuzzy clouds. (b) FISH images of interphase nuclei from uncultured amniocytes hybridized with probes specific for chromosomes 21 and 13. In the normal case (left), there are two clear red signals corresponding to the two copies of chromosome 21 and two green signals corresponding to chromosome 13. In the trisomy 21 case (right), there are three clear red signals in both interphase nuclei, indicating the presence of an extra copy of chromosome 21. Note the split red signal, which could cause problems in interpreting the number of chromosomes present. By convention, a score as a single chromosome spot is assigned if the distance between spots is smaller than their size in any focal plane. Note also that one of the green signals is much smaller than the other (arrow), in this case indicating that the chromosome is lying in a different focal plane. Thus, it is very important to focus up and down when analysing interphase nuclei for aneuploidy diagnosis by microscopy. (c) FISH images of interphase nuclei from uncultured amniocytes from a normal male, hybridized with chromosome 18, X and Y probes. The image on the left shows the X-and Y-chromosomes in green and red, respectively, indicating a normal XY male. The image on the right shows the same nuclei with the chromosome 18 signals in aqua. Note that, as the left nucleus is out of focus, the Y signal appears split and the chromosome 18 spots are very diffuse and hardly identifiable.
2001). The first developed probes were derived from DNA of flow-sorted whole chromosomes and used for prenatal diagnosis of trisomy 21, 13 or 18 by Kuo et al (1991) on uncultured amniotic fluid cell nuclei. The drawback of this approach is that the signals obtained may be quite diffuse, as chromosomes at interphase of the cell cycle often appear much less condensed than those at metaphase, if standard fixation technologies are used (Fig. 2a) . For aneuploidy diagnosis, FISH with smaller probes is advantageous, as signals appear as more distinct dots. Normal samples are expected to show two dots per cell nucleus, whereas those that are trisomic will show three dots (Fig. 2b,c) . Initially, a variety of such probes was developed in research laboratories. More recently, probe sets have been produced commercially (Vysis) and are applied in batches, highlighting chromosomes 13 and 21 in one hybridization and 18 plus X and Y in another.
It should be noted that whole chromosome paints may in fact be successfully used, measuring the fluorescence ratio between a target chromosome in relation to a standard of similar size, not likely to be represented as a trisomy at the time of prenatal diagnosis (Truong et al., 2003) .
QF-PCR
The most common type of QF-PCR involves the amplification of chromosome-specific, repeated DNA sequences known as small (short) tandem repeats (STRs). STRs are stable and polymorphic, that is, they vary in length between subjects, depending on the number of times the tri-, tetra-or penta-nucleotides are repeated. The sample DNA is amplified by PCR using fluorescent primers so that products can be visualized and quantified as peak areas of the respective repeat lengths using an automated DNA sequencer with the Gene-Scan software (Fig. 3) . DNA amplified from normal subjects who are heterozygous (have alleles of different lengths) is expected to show two peaks with the same area. DNA amplified from subjects who are trisomic will exhibit either an extra peak (being triallelic) with the same area, or only two peaks (being diallelic), one of them twice as large as the other. By convention (agreed at a Symposium in Austria in 2001 arranged by Barbara Pertl), samples that are diallelic, containing two peaks with area ratios of the shorter and the longer allele within the range 0.8-1.4, are considered to be normal. In contrast, diallelic samples with ratios <0.65 or >1.8, are considered to be trisomic (for examples, see Fig.3a -c).
STRs that are highly polymorphic have been commonly used as markers for QF-PCR. However, single nucleotide polymorphisms (SNPs), which are much more frequent in the human genome, present an alternative option, likely to become more commonly applied in future. In addition, unique DNA sequences may be applied, for example using the novel multiplex ligation-dependent probe amplification (MLPA) technique (Schouten et al., 2002) .
FISH requires larger samples and is more labour intensive than QF-PCR

FISH
Aneuploidy diagnosis by FISH is performed on preparations made from around 1.0-1.5 ml of amniotic fluid. After centrifugation, cells in the pellet are fixed and placed on microscopy slides and hybridized with FISH probes (Klinger et al., 1992) . Samples may be handled in batches but the process is still quite time consuming (Grimshaw et al., 2003) . Some reduction in time may be achieved by the use of automatic harvesters (for example, Hamilton). The most time-consuming part of the interphase FISH procedure concerns fluorescence microscopy, and involves spot counting of 25-50 nuclei with 
QF-PCR
QF-PCR can accommodate smaller sized samples than are required for FISH for prenatal aneuploidy diagnosis. Routinely, DNA is extracted in batches from about 0.5-1.0 ml amniotic fluid per case, taken at about 15 weeks, followed by PCR amplification and gel electrophoresis on a DNA sequencer. An alternative option involves sampling the exo-coelomic fluid, which can take place much earlier, at 5 weeks (Jauniaux et al., 2003) . The analysis when carried out by the Gene-Scan software on an automated DNA sequencer (for example, Applied Biosystems) is expected to take about 5 min per sample. QF-PCR is more amenable to automation than FISH, and a large number of samples can be handled simultaneously, allowing substantial economy of scale (Grimshaw et al., 2003) .
The markers, specific for chromosomes 21, 13, 18, X and Y that have been used for QF-PCR, together with their heterozygosity, are exemplified (Table 2) . Original studies applied one marker at a time but several more recent reports describe the development of multiplex assays in which 4-12 markers are co-amplified in different combinations (Table 3) . Most often 1-3 multiplex assays are used for aneuploidy diagnosis with a minimum of two informative markers per chromosome required for confident diagnosis. Samples that are uninformative (or suspected to be abnormal) may be re-tested, using additional markers as a back-up.
In our view, the most taxing part of setting up a QF-PCR service for prenatal interphase diagnosis concerns optimization of the primers to be included in any one multiplex reaction. To date, there are no commercial STR multiplex primer kits available.
The risk for misdiagnosis by either FISH or QF-PCR is relatively small
FISH
There are now a large number of reports in the literature highlighting the efficacy of rapid prenatal aneuploidy diagnosis, using FISH probes on interphase nuclei. The experience gained so far with respect to the proportion of cases that are informative, and the risk for misdiagnosis, is summarized (Table 4) .
Some DNA sequences may be shared in common between different centromeres, and the initial FISH probes developed for certain centromeres cross-hybridized to others leading to diagnostic failures. The development of chromosome-specific probes, using unique DNA sequences has, to a large extent, eliminated this type of problem. Remaining diagnostic problems seen with the commercially available probe sets for chromosomes 21, 13, 18, X and Y include, in particular, constitutional heteromorphisms leading to false positive or false negative results (Table 5) .
The first prospective FISH study on interphase amniocytes, using probes for single copy-like signals of chromosomes 21, 18, 13, X and Y appeared more than a decade ago (Klinger et al., 1992) . This seminal investigation was followed only a year later by another (and much larger) prospective study involving 4500 samples, showing 90.2% informativeness when using region-specific probes for the same chromosomes (Ward et al., 1993) .
Many more recent literature reports have indicated a much higher informativeness. They also show that the risk of either over-or underdiagnosis of anueploidy for the target chromosomes is small by interphase FISH, using the 'gold standard' of karyotyping as a comparison (Table 4) . One recent review summarizes data on 29 039 cases (Tepperberg et al., 2001) . On the basis of their most recent series of 5197 informative tests, using the Aneuvysion probe set (Vysis), the authors predict a risk for a false positive result to be less than 1 in 30 000 cases and that of a false negative to be less than 1 in 4000. However, not all centres agree. Thus, for example, Weremowicz et al. (2001) comment that, in their experience, the sensitivity (the probability that the FISH test will accurately predict karyotypic aneuploidy) and specificity (the probability that the FISH test will accurately predict karyotypic normality) is much lower (Table 4) . It should be added that some discrepancies might in fact be expected between uncultured and cultured cell populations, particularly with respect to maternal cell contamination and mosaic cell lines. The reason for this is that during cell proliferation in vitro, Prenatal diagnosis of common chromosome disorders 285 some cell types may be preferentially selected against and thus lost for karyotyping.
QF-PCR
The first QF-PCR application involved X chromosome aneuploidy (Lubin et al., 1991) . This was followed by investigation of the trisomies 21, 13 and 18 in a relatively small number of cases in single or multiplex PCR reactions (Mansfield, 1993; Pertl et al., 1994; Adinolfi et al., 1995) . More recently, a number of reports on larger series have been published (Table 3) . Several other smaller studies confirm the high reliability and reproducibility of the QF-PCR assay (Findlay et al., 1998; Pertl et al., 1999; Yang et al., 1999; Chen et al., 2000; Bili et al., 2002) . False negative or false positive results using QF-PCR are rare, in particular when analysing autosomal chromosomes. The main problem QF-PCR has posed is when testing for sex chromosome abnormalities. When STRs specific for chromosome X are used, some samples from normal XX females may show homozygous QF-PCR patterns, indistinguishable from those produced by samples with a single X, as in Turner syndrome (Fig. 3f) . Incorporating additional X-chromosome markers into the analysis will reduce the likelihood of homozygosity. Cirigliano et al. (2002) further suggested that the addition of an autosomal marker (such as D21S1411) as an internal control for quantification of the X-chromosome marker HPRT may solve the problem.
It is important to note that the occurrence of an extra or missing signal (or abnormal ratios) for a single marker in an otherwise normal multiplex reaction may not necessarily represent a technical artefact. There is a possibility that this could be caused by a fetal constitutional duplication or deletion of the chromosome segment, where the marker is localized. In this situation, it is advisable to check the same in DNA from parental blood samples. It may also be prudent to test adjacent markers to identify the size of the suspected duplication or deletion, which may either constitute a harmless polymorphism or be associated with mental and/or physical handicap.
Maternal cell contamination may constitute more of a problem with FISH than with QF-PCR
It has been estimated that a large proportion of amniotic fluid samples (21.4%) is contaminated with some maternal cells. However, a much lower proportion (1-2%) is macroscopically blood stained, potentially leading to false negative diagnosis of fetal aneuploidy (Winsor et al., 1996) . For safety, many laboratories would discard any such heavily contaminated samples with respect to rapid prenatal diagnosis.
FISH
One of the disadvantages of FISH is that maternal and fetal XX cells per se are indistinguishable by FISH, rendering maternal cell contamination undetectable from female fetuses. This is not an uncommon reason for misdiagnosis (Table 5) . However, maternal cell contamination is readily detectable with male fetuses, as a mixture of XX and XY cells are then seen. (The same is found in cases of fetal true hermaphroditism but such cases are exceedingly rare.)
QF-PCR
In contrast to the situation with FISH, maternal cell contamination is readily detected by QF-PCR amplification of STRs. A characteristic pattern with extra alleles or skewed ratios between peaks for the target chromosomes is seen (Fig. 3g) . Macroscopically bloodstained samples showing such results have in the past generally been considered unsuitable for PCR diagnosis. Nevertheless, accurate diagnosis may often be achieved by careful comparison with profiles from maternal blood samples.
Constitutional fetal mosaicism remains a challenge by either method
A related problem is the diagnosis of constitutional fetal mosaicism, the occurrence of different fetal cell lines containing different numbers of chromosomes.
FISH
The sensitivity of the FISH probes is not 100% (Table 1) . Therefore, a relatively large number of cells (in the order of 25-50) have to be examined, and cutoff levels for proportions of apparently normal and apparently aneuploid nuclei set (Ward et al., 1993; Tepperberg et al., 2001 ). Low-grade mosaicism is likely to be missed. However, after karyotyping, FISH analysis of uncultured interphase amniocytes and chorionic villus cells may in fact aid diagnosis of any suspected constitutional mosaicism (Feldman et al., 2000; Siffroi et al., 2000) . The FISH approach, which allows a higher number of interphase nuclei to be examined, may be of special advantage with respect to the problem of confined placental mosaicism in chorionic villus samples (Quilter et al., 2001 ).
QF-PCR
Mosaicism poses a challenge also when using QF-PCR for prenatal diagnosis. Mann et al. (2001) 
A trend towards 'stand-alone' molecular tests
Special attention has been paid to the potential for using FISH or QF-PCR for the diagnosis of common aneuploidies as 'stand-alone' tests. Opinions are divided. Bearing in mind that both amniocentesis and CVS are invasive procedures with a risk for induced abortion, it has been argued that follow-up by karyotyping should be performed to detect those chromosome abnormalities (in particular those associated with more or less severe physical and mental handicap) not identifiable by the current molecular tests. The proportion of such abnormalities, undetectable by current FISH and QF-PCR aneuploidy assays is about 20-30%, but varies considerably depending on the reasons for testing (Ward et al., 1993; Evans et al., 1999; Lewin et al., 2000; Pergament et al., 2000; Thein et al., 2000; Homer et al., 2003) . For most women, when the indication for prenatal diagnosis is maternal age (in isolation or combined with maternal serum and ultrasonographic screening for fetal nuchal translucency), this risk is usually relatively low, in the order of 0.1-0.2% (Grimshaw et al., 2003) . In other words, in the low-risk group of women, the abnormality detection rate is around 99.8-99.9%. In contrast, once a structural abnormality of the fetus has been diagnosed using ultrasonography, the risk may be substantially increased. The risk for a fetal chromosome abnormality is also substantially increased when either parent is a carrier of a chromosome rearrangement such as a translocation, inversion or insertion. Neither FISH nor QF-PCR aneuploidy assays are applicable. Either karyotyping or specific molecular testing (Chen et al., 2001 ) is mandatory.
Standard karyotyping also discovers structural chromosome rearrangements in balanced form, undetectable by current FISH and QF-PCR approaches. Carriers of structural chromosome rearrangements (such as translocations, inversions and insertions) are common in the general population and occur with an incidence of around one in 300. The incidence is not increased in amniotic fluid samples or CVSs, and the fetal carrier status may thus be a coincidental finding. Carrier status often runs in families. Detecting a structural chromosome rearrangement by prenatal diagnosis makes possible the unravelling of large families, where many carriers may be offered appropriate counselling regarding their reproductive risk (including reduced fertility and increased risks for abortions and stillbirths and for having a liveborn child with a chromosome abnormality). This potential is lost by application of the molecular tests as a 'stand-alone' approach.
Summary and final remarks
FISH and QF-PCR constitute molecular methods that allow rapid and simple yet reliable prenatal diagnosis of targeted fetal chromosome disorders. Currently, these molecular tests are used for the detection of the most common abnormalities, trisomy 21, 13 and 18 (giving rise to the Down, Patau and Edward syndromes, respectively) and sex chromosome abnormalities (associated with the XXY-Klinefelter, XYY, XXX and X-Turner syndromes). These methods are applied to fetal nondividing cells and DNA obtained using the invasive procedures amniocentesis and CVS. The methods are used mainly as a preamble to traditional karyotyping, performed after in vitro cell culture, using an aliquot of the same sample. However, a debate continues about the potential advantage for introducing these as 'stand-alone' tests for routine prenatal chromosome diagnosis in lowrisk pregnancies (Ogilvie, 2003) . This would be a highly cost-effective policy in relation to the current practice of both molecular and traditional testing (Grimshaw et al., 2003) .
It is hoped that, in not too distant a future, the same technology may be applied for 'non-invasive' prenatal diagnosis on fetal cells or DNA retrieved from maternal blood samples, leading to a reduced requirement for invasive procedures that carry a risk for associated fetal loss. In the interim, the introduction of these targeted molecular methods per se may focus attention on the urgent need for appropriate information to be given to pregnant women (and their partners) regarding what fetal conditions may be looked for; and following discussions on the implications of the various disorders for child development, informed parental choices may be improved over and above the current situation (Marteau and Dormandy, 2001 ).
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